Does excessive daytime sleepiness affect your life?

If so, you may qualify for a narcolepsy clinical research study looking to find a new treatment option to help improve wakefulness.

About the Investigational Study Drug

TAK-994 is an investigational drug that, if approved, will be the first treatment of its kind. This oral treatment targets OX deficiency, working differently from approved Narcolepsy medications. OX deficiency plays an important role in Excessive Daytime Sleepiness (EDS), a common symptom associated with Narcolepsy.

By addressing OX deficiency, TAK-994 may address many symptoms associated with Narcolepsy.

Early study data shows that participants who received TAK-994 as part of the study, when compared to placebo (inactive drug) and baseline experienced:

  • A 30-minute improvement in wakefulness from baseline
    • Average waking period is determined by the Maintenance of Wakefulness Test (MWT) and is an important factor in measuring the effectiveness of Narcolepsy treatments.
  • Reduction in Epworth Sleepiness Scale (Measures daytime sleepiness)
  • 40% reduction in weekly cataplexy rate from baseline
    • Cataplexy is a sudden loss of muscle tone which can be triggered by strong emotion. This can include slurred speech to complete weakness of most muscles which can last up to a few minutes.

What does this mean?

While it is too early to draw any definitive conclusions, this early data suggests that the TAK-994 study drug may offer an important improvement in effectiveness compared to currently approved therapies.

This could represent a significant improvement in wakefulness and alertness as well as an improved quality of life for people living with narcolepsy.

Answer a few questions to see if you may qualify for the SPARKLE 1501 Study.

Answer questions